{
 "licence": "CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/), except the WHO ATC codes and DDD values and the NICE, SMC and G-BA content, which are cited under their own terms and are not licensed here",
 "licensor": "Loïc Rigal, Open Health Prices, https://access.loicrigal.com",
 "attribution_required": [
  {
   "source": "fr-bdpm",
   "text": "Source: base de données publique des médicaments, https://base-donnees-publique.medicaments.gouv.fr, mise à jour du 8 octobre 2026."
  },
  {
   "source": "es-nomenclator",
   "text": "Fuente: Ministerio de Sanidad, Nomenclátor de facturación de octubre 2026."
  },
  {
   "source": "es-cima",
   "text": "Fuente: AEMPS, CIMA, consultado el 9 de octubre de 2026."
  },
  {
   "source": "uk-drug-tariff",
   "text": "Drug Tariff Part VIIIA October 2026, NHSBSA Copyright 2026. This information is licenced under the terms of the Open Government Licence."
  },
  {
   "source": "uk-dmd",
   "text": "NHS Dictionary of Medicines and Devices (dm+d), NHSBSA Copyright 2026. This information is licenced under the terms of the Open Government Licence."
  },
  {
   "source": "who-atcddd",
   "text": "ATC codes and DDDs: WHO Collaborating Centre for Drug Statistics Methodology, ATC/DDD Index 2026."
  },
  {
   "source": "ecb",
   "text": "Exchange rates: European Central Bank, euro reference rates of 9 October 2026."
  },
  {
   "source": "ema",
   "text": "Source: European Medicines Agency, medicine data of 9 October 2026, https://www.ema.europa.eu/en/medicines/download-medicine-data"
  },
  {
   "source": "dysnet-teratogens",
   "text": "Teratogen register, DysNet, the dysmelia network, https://www.dysnet.org/knowledge/teratogens/, data built 12 September 2026, CC BY 4.0."
  },
  {
   "source": "nice",
   "text": "Source: National Institute for Health and Care Excellence, technology appraisal guidance, https://www.nice.org.uk"
  },
  {
   "source": "smc",
   "text": "Source: Scottish Medicines Consortium, https://scottishmedicines.org.uk"
  },
  {
   "source": "de-gba",
   "text": "Quelle: Gemeinsamer Bundesausschuss, https://www.g-ba.de"
  },
  {
   "source": "es-aemps-ipt",
   "text": "Fuente: AEMPS, informes de posicionamiento terapéutico, consultado el 9 de octubre de 2026."
  },
  {
   "source": "pubmed",
   "text": "Courtesy of the U.S. National Library of Medicine."
  },
  {
   "source": "who-eml",
   "text": "WHO Model List of Essential Medicines, electronic version (eEML), World Health Organization, CC BY 3.0 IGO."
  },
  {
   "source": "fr-lpp",
   "text": "Source : Assurance Maladie, liste des produits et prestations, version 905 du 8 octobre 2026."
  },
  {
   "source": "us-dmepos",
   "text": "Source: CMS, DMEPOS fee schedule, October 2026."
  },
  {
   "source": "us-hcpcs",
   "text": "Source: CMS, HCPCS Level II file, October 2026."
  },
  {
   "source": "au-prescribed-list",
   "text": "Based on content from the Federal Register of Legislation at 9 October 2026. For the latest information on Australian Government legislation please go to https://www.legislation.gov.au."
  },
  {
   "source": "eu-emdn",
   "text": "EMDN: European Commission, European Medical Device Nomenclature, version 2026."
  }
 ],
 "terms": "https://access.loicrigal.com/en/sources/",
 "generated": "2026-10-09",
 "ipt_records": 823,
 "medicines": {
  "sodium-valproate": {
   "nice": [],
   "smc": [],
   "gba": [],
   "ipt": []
  },
  "isotretinoin": {
   "nice": [],
   "smc": [],
   "gba": [],
   "ipt": []
  },
  "methotrexate": {
   "nice": [],
   "smc": [
    {
     "id": "724/11",
     "medicine": "methotrexate 50mg/ml solution for injection (Metoject®)",
     "date": "2011-08-08",
     "submission": "Abbreviated",
     "status": null,
     "indication": "Polyarthritic forms of severe active Juvenile Idiopathic Arthritis",
     "url": "https://scottishmedicines.org.uk/medicines-advice/methotrexate-50mgml-solution-for-injection-metoject-abbreviatedsubmission-72411/"
    },
    {
     "id": "573/09",
     "medicine": "methotrexate (Metoject 50mg/ml)",
     "date": "2009-10-12",
     "submission": "Abbreviated",
     "status": null,
     "indication": "Severe recalcitrant disabling psoriasis",
     "url": "https://scottishmedicines.org.uk/medicines-advice/methotrexate-metoject-50mgml-abbreviatedsubmission-57309/"
    },
    {
     "id": "332/06",
     "medicine": "methotrexate injection 10mg/ml, (Metoject)",
     "date": "2006-12-11",
     "submission": "Abbreviated",
     "status": null,
     "indication": "Severe active rheumatoid arthritis",
     "url": "https://scottishmedicines.org.uk/medicines-advice/methotrexate-injection-10mgml-metoject-abbreviatedsubmission-33206/"
    }
   ],
   "gba": [],
   "ipt": []
  },
  "lithium": {
   "nice": [],
   "smc": [],
   "gba": [],
   "ipt": []
  },
  "warfarin": {
   "nice": [],
   "smc": [],
   "gba": [],
   "ipt": []
  },
  "topiramate": {
   "nice": [],
   "smc": [
    {
     "id": "297/06",
     "medicine": "topiramate 25, 50mg tablets, 25, 50mg sprinkle capsules (Topamax)",
     "date": "2006-09-11",
     "submission": "Full",
     "status": "Restricted",
     "indication": "Prophylaxis of migraine headache in adults",
     "url": "https://scottishmedicines.org.uk/medicines-advice/topiramate-25-50mg-tablets-25-50mg-sprinkle-capsules-topamax-fullsubmission-29706/"
    },
    {
     "id": "75/03",
     "medicine": "Topiramate (Topamax)",
     "date": "2004-01-12",
     "submission": "Full",
     "status": "Restricted",
     "indication": "Epilepsy",
     "url": "https://scottishmedicines.org.uk/medicines-advice/topiramate-topamax-fullsubmission-7503/"
    }
   ],
   "gba": [],
   "ipt": []
  },
  "mycophenolate-mofetil": {
   "nice": [
    {
     "ref": "TA481",
     "title": "Immunosuppressive therapy for kidney transplant in adults",
     "url": "https://www.nice.org.uk/guidance/ta481",
     "published": "2017-10-11",
     "updated": "2017-10-11",
     "status": "Published"
    },
    {
     "ref": "TA482",
     "title": "Immunosuppressive therapy for kidney transplant in children and young people",
     "url": "https://www.nice.org.uk/guidance/ta482",
     "published": "2017-10-11",
     "updated": "2017-10-11",
     "status": "Published"
    }
   ],
   "smc": [
    {
     "id": "144/04",
     "medicine": "Mycophenolate sodium (Myfortic®)",
     "date": "2005-01-10",
     "submission": "Full",
     "status": "Accepted",
     "indication": "In combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in adult patients receiving allogeneic renal transplants",
     "url": "https://scottishmedicines.org.uk/medicines-advice/mycophenolate-sodium-myfortic-fullsubmission-14404/"
    }
   ],
   "gba": [],
   "ipt": []
  },
  "adalimumab": {
   "nice": [
    {
     "ref": "TA715",
     "title": "Adalimumab , etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed",
     "url": "https://www.nice.org.uk/guidance/ta715",
     "published": "2021-07-14",
     "updated": "2021-07-14",
     "status": "Published"
    },
    {
     "ref": "TA460",
     "title": "Adalimumab and dexamethasone for treating non-infectious uveitis",
     "url": "https://www.nice.org.uk/guidance/ta460",
     "published": "2017-07-26",
     "updated": "2017-07-26",
     "status": "Published"
    },
    {
     "ref": "TA455",
     "title": "Adalimumab , etanercept and ustekinumab for treating plaque psoriasis in children and young people",
     "url": "https://www.nice.org.uk/guidance/ta455",
     "published": "2017-07-12",
     "updated": "2017-07-12",
     "status": "Published"
    },
    {
     "ref": "TA392",
     "title": "Adalimumab for treating moderate to severe hidradenitis suppurativa",
     "url": "https://www.nice.org.uk/guidance/ta392",
     "published": "2016-06-22",
     "updated": "2016-06-22",
     "status": "Published"
    },
    {
     "ref": "TA375",
     "title": "Adalimumab , etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed",
     "url": "https://www.nice.org.uk/guidance/ta375",
     "published": "2016-01-26",
     "updated": "2016-01-26",
     "status": "Published"
    },
    {
     "ref": "TA373",
     "title": "Abatacept, adalimumab , etanercept and tocilizumab for treating juvenile idiopathic arthritis",
     "url": "https://www.nice.org.uk/guidance/ta373",
     "published": "2015-12-16",
     "updated": "2015-12-16",
     "status": "Published"
    },
    {
     "ref": "TA329",
     "title": "Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy",
     "url": "https://www.nice.org.uk/guidance/ta329",
     "published": "2015-02-25",
     "updated": "2015-02-25",
     "status": "Published"
    },
    {
     "ref": "TA199",
     "title": "Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis",
     "url": "https://www.nice.org.uk/guidance/ta199",
     "published": "2010-08-25",
     "updated": "2010-08-25",
     "status": "Published"
    },
    {
     "ref": "TA195",
     "title": "Adalimumab , etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor",
     "url": "https://www.nice.org.uk/guidance/ta195",
     "published": "2010-08-25",
     "updated": "2010-08-25",
     "status": "Published"
    },
    {
     "ref": "TA187",
     "title": "Infliximab and adalimumab for the treatment of Crohn's disease",
     "url": "https://www.nice.org.uk/guidance/ta187",
     "published": "2010-05-19",
     "updated": "2010-05-19",
     "status": "Published"
    },
    {
     "ref": "TA146",
     "title": "Adalimumab for treating moderate to severe plaque psoriasis",
     "url": "https://www.nice.org.uk/guidance/ta146",
     "published": "2008-06-25",
     "updated": "2008-06-25",
     "status": "Published"
    },
    {
     "ref": "TA125",
     "title": "Adalimumab for the treatment of psoriatic arthritis",
     "url": "https://www.nice.org.uk/guidance/ta125",
     "published": "",
     "updated": "",
     "status": ""
    },
    {
     "ref": "TA143",
     "title": "Adalimumab , etanercept and infliximab for ankylosing spondylitis",
     "url": "https://www.nice.org.uk/guidance/ta143",
     "published": "",
     "updated": "",
     "status": ""
    },
    {
     "ref": "TA130",
     "title": "Adalimumab , etanercept and infliximab for the treatment of rheumatoid arthritis",
     "url": "https://www.nice.org.uk/guidance/ta130",
     "published": "",
     "updated": "",
     "status": ""
    },
    {
     "ref": "TA262",
     "title": "Adalimumab for the treatment of moderate to severe ulcerative colitis (terminated appraisal)",
     "url": "https://www.nice.org.uk/guidance/ta262",
     "published": "",
     "updated": "",
     "status": ""
    }
   ],
   "smc": [
    {
     "id": "1305/18",
     "medicine": "adalimumab (Humira)",
     "date": "2018-01-15",
     "submission": "Non submission",
     "status": "Not recommended",
     "indication": "Treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.",
     "url": "https://scottishmedicines.org.uk/medicines-advice/adalimumab-humira-nonsubmission-130518/"
    },
    {
     "id": "1243/17",
     "medicine": "adalimumab (Humira)",
     "date": "2017-06-12",
     "submission": "Abbreviated",
     "status": "Accepted",
     "indication": "for treatment of active moderate to severe hidradenitis suppurativa (HS) (acne inversa) in adolescents from 12 years of age with an inadequate response to conventional systemic HS therapy.",
     "url": "https://scottishmedicines.org.uk/medicines-advice/adalimumab-humira-abbreviatedsubmission-124317/"
    },
    {
     "id": "1208/16",
     "medicine": "adalimumab (Humira)",
     "date": "2016-11-07",
     "submission": "Non submission",
     "status": "Not recommended",
     "indication": "Treatment of moderately active Crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies",
     "url": "https://scottishmedicines.org.uk/medicines-advice/adalimumab-humira-nonsubmission-120816/"
    },
    {
     "id": "1209/16",
     "medicine": "adalimumab (Humira)",
     "date": "2016-11-07",
     "submission": "Non submission",
     "status": "Superseded",
     "indication": "Treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate.",
     "url": "https://scottishmedicines.org.uk/medicines-advice/adalimumab-humira-nonsubmission-120916/"
    },
    {
     "id": "1173/16",
     "medicine": "adalimumab (Humira)",
     "date": "2016-07-11",
     "submission": "Non submission",
     "status": "Not recommended",
     "indication": "Treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. (This licence extension relates to previous SMC advice (468/08).",
     "url": "https://scottishmedicines.org.uk/medicines-advice/adalimumab-humira-nonsubmission-117316/"
    },
    {
     "id": "1143/16",
     "medicine": "adalimumab (Humira)",
     "date": "2016-05-09",
     "submission": "Full",
     "status": "Accepted",
     "indication": "Treatment of active moderate to severe hidradenitis suppurativa (HS) (acne inversa) in adult patients with an inadequate response to conventional systemic HS therapy.",
     "url": "https://scottishmedicines.org.uk/medicines-advice/adalimumab-humira-fullsubmission-114316/"
    },
    {
     "id": "1068/15",
     "medicine": "adalimumab (Humira)",
     "date": "2015-07-13",
     "submission": "Abbreviated",
     "status": "Superseded",
     "indication": "Treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies.",
     "url": "https://scottishmedicines.org.uk/medicines-advice/adalimumab-humira-abbreviatedsubmission-106815/"
    },
    {
     "id": "1050/15",
     "medicine": "adalimumab (Humira)",
     "date": "2015-05-11",
     "submission": "Abbreviated",
     "status": "Restricted",
     "indication": "For the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy.",
     "url": "https://scottishmedicines.org.uk/medicines-advice/adalimumab-humira-abbreviatedsubmission-105015/"
    },
    {
     "id": "881/13",
     "medicine": "adalimumab (Humira)",
     "date": "2013-07-08",
     "submission": "Abbreviated",
     "status": "Superseded",
     "indication": "In combination with methotrexate for the treatment of active polyarticular juvenile idiopathic arthritis, in children and adolescents aged 2 to 17 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Adalimumab can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Adalimumab has not been studied in children aged less than 2 years.",
     "url": "https://scottishmedicines.org.uk/medicines-advice/adalimumab-humira-abbreviatedsubmission-88113/"
    },
    {
     "id": "880/13",
     "medicine": "adalimumab (Humira)",
     "date": "2013-07-08",
     "submission": "Abbreviated",
     "status": "Restricted",
     "indication": "For the treatment of severe active Crohn's disease in paediatric patients (6 to 17 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy, a corticosteroid, and an immunomodulator, or who are intolerant to or have contraindications for such therapies.",
     "url": "https://scottishmedicines.org.uk/medicines-advice/adalimumab-humira-abbreviatedsubmission-88013/"
    },
    {
     "id": "858/13",
     "medicine": "adalimumab (Humira)",
     "date": "2013-04-08",
     "submission": "Full",
     "status": "Superseded",
     "indication": "For the treatment of adults with severe axial spondyloarthritis without radiographic evidence of ankylosing spondylitis (nr-axSpA) but with objective signs of inflammation by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).",
     "url": "https://scottishmedicines.org.uk/medicines-advice/adalimumab-humira-fullsubmission-85813/"
    },
    {
     "id": "824/12",
     "medicine": "adalimumab (Humira)",
     "date": "2012-11-12",
     "submission": "Non submission",
     "status": "Not recommended",
     "indication": "Treatment of moderately active Crohn's disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.",
     "url": "https://scottishmedicines.org.uk/medicines-advice/adalimumab-humira-nonsubmission-82412/"
    },
    {
     "id": "800/12",
     "medicine": "adalimumab (Humira)",
     "date": "2012-07-09",
     "submission": "Non submission",
     "status": "Superseded",
     "indication": "Treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.",
     "url": "https://scottishmedicines.org.uk/medicines-advice/adalimumab-humira-nonsubmission-80012/"
    },
    {
     "id": "738/11",
     "medicine": "adalimumab (Humira)",
     "date": "2011-11-07",
     "submission": "Abbreviated",
     "status": "Superseded",
     "indication": "In combination with methotrexate for the treatment of active polyarticular juvenile idiopathic arthritis, in children and adolescents aged 4 to 17 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Adalimumab can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Adalimumab has not been studied in children aged less than 4 years.",
     "url": "https://scottishmedicines.org.uk/medicines-advice/adalimumab-humira-abbreviatedsubmission-73811/"
    },
    {
     "id": "533/09",
     "medicine": "adalimumab (Humira)",
     "date": "2009-02-09",
     "submission": "Abbreviated",
     "status": "Superseded",
     "indication": "Active polyarticular juvenile idiopathic arthritis in adolescents",
     "url": "https://scottishmedicines.org.uk/medicines-advice/adalimumab-humira-abbreviatedsubmission-53309/"
    },
    {
     "id": "468/08",
     "medicine": "adalimumab (Humira)",
     "date": "2008-06-09",
     "submission": "Full",
     "status": "Restricted",
     "indication": "Moderate to severe chronic plaque psoriasis in adult patients",
     "url": "https://scottishmedicines.org.uk/medicines-advice/adalimumab-humira-fullsubmission-46808/"
    },
    {
     "id": "417/07",
     "medicine": "adalimumab 40mg solution for injection (Humira)",
     "date": "2007-11-12",
     "submission": "Full",
     "status": "Superseded",
     "indication": "Severe active crohn' s disease",
     "url": "https://scottishmedicines.org.uk/medicines-advice/adalimumab-humira-fullsubmission-41707/"
    },
    {
     "id": "300/06",
     "medicine": "adalimumab 40mg pre-filled syringe (Humira)",
     "date": "2006-12-11",
     "submission": "Full",
     "status": "Superseded",
     "indication": "Severe active ankylosing spondylitis",
     "url": "https://scottishmedicines.org.uk/medicines-advice/adalimumab-humira-fullsubmission-30006/"
    },
    {
     "id": "218/05",
     "medicine": "adalimumab (Humira)",
     "date": "2005-12-12",
     "submission": "Full",
     "status": "Superseded",
     "indication": "active and progressive psoriatic arthritis.",
     "url": "https://scottishmedicines.org.uk/medicines-advice/adalimumab-humira-fullsubmission-21805/"
    },
    {
     "id": "81/03",
     "medicine": "adalimumab (Humira)",
     "date": "2003-12-08",
     "submission": "Full",
     "status": "Superseded",
     "indication": "Rheumatoid arthritis",
     "url": "https://scottishmedicines.org.uk/medicines-advice/adalimumab-humira-fullsubmission-8103/"
    }
   ],
   "gba": [],
   "ipt": []
  },
  "letrozole": {
   "nice": [],
   "smc": [
    {
     "id": "251/06",
     "medicine": "letrozole (Femara)",
     "date": "2006-05-08",
     "submission": "Full",
     "status": "Restricted",
     "indication": "Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer",
     "url": "https://scottishmedicines.org.uk/medicines-advice/letrozole-femara-fullsubmission-25106/"
    },
    {
     "id": "152/05",
     "medicine": "Letrozole (Femara®)",
     "date": "2005-03-07",
     "submission": "Full",
     "status": "Restricted",
     "indication": "Invasive early breast cancer in postmenopausal women who have already received standard tamoxifen therapy.",
     "url": "https://scottishmedicines.org.uk/medicines-advice/letrozole-femara-fullsubmission-15205/"
    }
   ],
   "gba": [],
   "ipt": []
  },
  "atorvastatin": {
   "nice": [],
   "smc": [
    {
     "id": "766/12",
     "medicine": "atorvastatin (Lipitor)",
     "date": "2012-03-12",
     "submission": "Abbreviated",
     "status": "Accepted",
     "indication": "Chewable tablets which have been developed for the treatment of hypercholesterolaemia in adolescents and children aged 10 years or older.",
     "url": "https://scottishmedicines.org.uk/medicines-advice/atorvastatin-lipitor-abbreviatedsubmission-76612/"
    },
    {
     "id": "202/05",
     "medicine": "Atorvastatin (Lipitor®)",
     "date": "2005-10-10",
     "submission": "Abbreviated",
     "status": "Restricted",
     "indication": "Reduction of elevated total cholesterol, LDL-cholesterol, apolipoprotein B and triglycerides in children aged 10 years and older with primary hypercholesterolaemia, heterozygous familial hypercholeste",
     "url": "https://scottishmedicines.org.uk/medicines-advice/atorvastatin-lipitor-abbreviatedsubmission-20205/"
    }
   ],
   "gba": [],
   "ipt": []
  },
  "metformin": {
   "nice": [],
   "smc": [
    {
     "id": "1308/18",
     "medicine": "metformin hydrochloride (Glucophage)",
     "date": "2018-01-15",
     "submission": "Non submission",
     "status": "Not recommended",
     "indication": "Reduction in the risk or delay of the onset of type 2 diabetes mellitus in adult, overweight patients with impaired glucose tolerance and/or impaired fasting glucose, and/or increased HbA1C who are: • at high risk for developing overt type 2 diabetes mellitus and • still progressing towards type 2 diabetes mellitus despite implementation of intensive lifestyle change for 3 to 6 months.",
     "url": "https://scottishmedicines.org.uk/medicines-advice/metformin-hydrochloride-glucophage-nonsubmission-130818/"
    },
    {
     "id": "610/10",
     "medicine": "metformin hydrochloride (Glucophage) 500mg/1000mg Powder for Solution",
     "date": "2010-04-12",
     "submission": "Abbreviated",
     "status": null,
     "indication": "treatment of type 2 diabetes mellitus",
     "url": "https://scottishmedicines.org.uk/medicines-advice/metformin-hydrochloride-glucophage-500mg1000mg-powder-for-solution-abbreviatedsubmission-61010/"
    },
    {
     "id": "148/04",
     "medicine": "Metformin hydrochloride (Glucophage SR®)",
     "date": "2005-03-07",
     "submission": "Full",
     "status": "Not recommended",
     "indication": "Type-2 diabetes mellitus",
     "url": "https://scottishmedicines.org.uk/medicines-advice/metformin-hydrochloride-glucophage-sr-fullsubmission-14804/"
    }
   ],
   "gba": [],
   "ipt": []
  },
  "amlodipine": {
   "nice": [],
   "smc": [
    {
     "id": "350/07",
     "medicine": "amlodipine besylate/valsartan (Exforge®)",
     "date": "2007-03-12",
     "submission": "Abbreviated",
     "status": null,
     "indication": "For patients whose blood pressure is not adequately controlled on amlodipine or valsartan monotherapy.",
     "url": "https://scottishmedicines.org.uk/medicines-advice/amlodipine-besylatevalsartan-exforge-abbreviatedsubmission-35007/"
    }
   ],
   "gba": [],
   "ipt": []
  },
  "omeprazole": {
   "nice": [],
   "smc": [],
   "gba": [],
   "ipt": []
  },
  "levothyroxine": {
   "nice": [],
   "smc": [],
   "gba": [],
   "ipt": []
  },
  "sertraline": {
   "nice": [],
   "smc": [
    {
     "id": "68/03",
     "medicine": "Sertraline (Lustral®)",
     "date": "2003-11-10",
     "submission": "Full",
     "status": "Not recommended",
     "indication": "Post-traumatic stress disorder in women",
     "url": "https://scottishmedicines.org.uk/medicines-advice/sertraline-lustral-fullsubmission-6803/"
    }
   ],
   "gba": [],
   "ipt": []
  },
  "amoxicillin": {
   "nice": [],
   "smc": [],
   "gba": [],
   "ipt": []
  },
  "salbutamol": {
   "nice": [],
   "smc": [
    {
     "id": "504/08",
     "medicine": "salbutamol sulphate (Salbulin MDPI Novoliser)",
     "date": "2008-10-13",
     "submission": "Abbreviated",
     "status": "Accepted",
     "indication": "For patients aged six years and over with reversible airways obstruction, such as asthma, for the relief and prevention of asthma symptoms",
     "url": "https://scottishmedicines.org.uk/medicines-advice/salbutamol-sulphate-salbulin-mdpi-novoliser-abbreviatedsubmission-50408/"
    }
   ],
   "gba": [],
   "ipt": []
  },
  "apixaban": {
   "nice": [
    {
     "ref": "TA341",
     "title": "Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism",
     "url": "https://www.nice.org.uk/guidance/ta341",
     "published": "2015-06-04",
     "updated": "2015-06-04",
     "status": "Published"
    },
    {
     "ref": "TA275",
     "title": "Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation",
     "url": "https://www.nice.org.uk/guidance/ta275",
     "published": "2013-02-27",
     "updated": "2021-07-02",
     "status": "Published"
    },
    {
     "ref": "TA245",
     "title": "Apixaban for preventing venous thromboembolism after hip or knee replacement surgery",
     "url": "https://www.nice.org.uk/guidance/ta245",
     "published": "2012-01-25",
     "updated": "2012-01-25",
     "status": "Published"
    }
   ],
   "smc": [
    {
     "id": "1029/15",
     "medicine": "apixaban (Eliquis)",
     "date": "2015-03-09",
     "submission": "Full",
     "status": "Accepted",
     "indication": "Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrent DVT and PE in adults.",
     "url": "https://scottishmedicines.org.uk/medicines-advice/apixaban-eliquis-fullsubmission-102915/"
    },
    {
     "id": "836/13",
     "medicine": "apixaban (Eliquis)",
     "date": "2013-02-11",
     "submission": "Full",
     "status": "Accepted",
     "indication": "For the prevention of stroke and systemic embolism (SE) in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors such as prior stroke or transient ischaemic attack(TIA): age ≥75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYYA Class ≥ II).",
     "url": "https://scottishmedicines.org.uk/medicines-advice/apixaban-eliquis-fullsubmission-83613/"
    },
    {
     "id": "741/11",
     "medicine": "apixaban (Eliquis)",
     "date": "2011-12-12",
     "submission": "Full",
     "status": "Accepted",
     "indication": "For the treatment of venous thromboembolic events (VTE) in adult patients who have undergone elective hip (THR) or knee (TKR) replacement surgery.",
     "url": "https://scottishmedicines.org.uk/medicines-advice/apixaban-eliquis-fullsubmission-74111/"
    }
   ],
   "gba": [
    {
     "id": 132,
     "url": "https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/132/",
     "vorgang": "2014-09-01-D-126",
     "title_de": "Apixaban (neues Anwendungsgebiet: Behandlung und Prophylaxe von Venenthrombosen und Lungenembolien)",
     "brand": "Eliquis",
     "decisions_de": "Beschluss vom 19. Februar 2015",
     "decision_date": "2015-02-19",
     "banz": "BAnz AT 24.03.2015 B2",
     "text_url": "https://www.g-ba.de/downloads/91-1385-132/2015-02-19_Geltende-Fassung_Apixaban_nAWG_D-126.pdf",
     "indication_de": "Behandlung von tiefen Venenthrombosen (TVT) und Lungenembolien (LE) sowie Prophylaxe von rezidivierenden TVT und LE bei Erwachsenen.",
     "groups": [
      {
       "group_de": "a) Initial-Behandlung einer tiefen Venenthrombose (TVT) bzw. einer Lungenembolie (LE) und parallel einzuleitende Prophylaxe bei Erwachsenen (für eine Behandlung bis 6 Monate)",
       "comparator_de": "Niedermolekulare Heparine (z. B. Enoxaparin); Vitamin-K-Antagonisten",
       "verdict_de": "Hinweis auf einen geringen Zusatznutzen",
       "cost": {
        "label_de": "Jahrestherapiekosten pro Patient (gemeinsame Kostenabbildung beider Behandlungsphasen)",
        "text": "562,06 €",
        "min": 562.06,
        "max": 562.06,
        "comparator_de": "Phenprocoumon 15,70 € - 47,10 €; Warfarin 16,26 € - 65,04 €; Enoxaparin-Natrium 100,22 €",
        "currency": "EUR",
        "kind": "HTA figure",
        "source_id": "de-gba",
        "url": "https://www.g-ba.de/downloads/91-1385-132/2015-02-19_Geltende-Fassung_Apixaban_nAWG_D-126.pdf",
        "date_read": "2026-10-09",
        "line": "G-BA 2014-09-01-D-126, Beschluss vom 19. Februar 2015, BAnz AT 24.03.2015 B2"
       }
      },
      {
       "group_de": "b) Langzeitprophylaxe von rezidivierenden tiefen Venenthrombosen (TVT) bzw. einer Lungenembolie (LE) bei Erwachsenen (nach Abschluss einer 6-monatigen Behandlung der TVT oder LE), für die eine weiterführende Antikoagulation angezeigt ist",
       "comparator_de": "Vitamin-K-Antagonisten",
       "verdict_de": "Der Zusatznutzen gilt als nicht belegt.",
       "cost": {
        "label_de": "Jahrestherapiekosten pro Patient",
        "text": "1 025,76 €",
        "min": 1025.76,
        "max": 1025.76,
        "comparator_de": "Phenprocoumon 28,65 € - 85,96 €; Warfarin 29,67 € - 118,70 €",
        "currency": "EUR",
        "kind": "HTA figure",
        "source_id": "de-gba",
        "url": "https://www.g-ba.de/downloads/91-1385-132/2015-02-19_Geltende-Fassung_Apixaban_nAWG_D-126.pdf",
        "date_read": "2026-10-09",
        "line": "G-BA 2014-09-01-D-126, Beschluss vom 19. Februar 2015, BAnz AT 24.03.2015 B2"
       }
      }
     ]
    },
    {
     "id": 57,
     "url": "https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/57/",
     "vorgang": "2013-01-01-D-053",
     "title_de": "Apixaban (neues Anwendungsgebiet: Prophylaxe von Schlaganfällen und systemischen Embolien)",
     "brand": "Eliquis",
     "decisions_de": "Beschluss vom 20. Juni 2013",
     "decision_date": "2013-06-20",
     "banz": "BAnz AT 01.08.2013 B4",
     "text_url": "https://www.g-ba.de/downloads/91-1385-57/2013-06-20_Geltende-Fassung_Apixaban_nAWG_D-053.pdf",
     "indication_de": "Zur Prophylaxe von Schlaganfällen und systemischen Embolien bei erwachsenen Patienten mit nicht-valvulärem Vorhofflimmern (NVAF) und einem oder mehreren Risikofaktoren.",
     "groups": [
      {
       "group_de": null,
       "comparator_de": "Vitamin-K-Antagonisten",
       "verdict_de": "Hinweis für einen geringen Zusatznutzen.",
       "cost": {
        "label_de": "Jahrestherapiekosten pro Patient",
        "text": "1 277,50 €",
        "min": 1277.5,
        "max": 1277.5,
        "comparator_de": "Vitamin-K-Antagonisten 36,70 € - 125,45 € (Warfarin), 21,70 € - 93,58 € (Phenprocoumon)",
        "currency": "EUR",
        "kind": "HTA figure",
        "source_id": "de-gba",
        "url": "https://www.g-ba.de/downloads/91-1385-57/2013-06-20_Geltende-Fassung_Apixaban_nAWG_D-053.pdf",
        "date_read": "2026-10-09",
        "line": "G-BA 2013-01-01-D-053, Beschluss vom 20. Juni 2013, BAnz AT 01.08.2013 B4"
       }
      }
     ]
    },
    {
     "id": 5,
     "url": "https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/5/",
     "vorgang": "2011-06-15-D-009",
     "title_de": "Apixaban (Prophylaxe venöser Thromboembolien)",
     "brand": "Eliquis",
     "decisions_de": "Beschluss vom 7. Juni 2012 / 6. September 2012",
     "decision_date": "2012-09-06",
     "banz": "BAnz AT 03.07.2012 B2 / BAnz AT 20.09.2012 B3",
     "text_url": "https://www.g-ba.de/downloads/91-1385-5/2012-09-06_Geltende-Fassung_Apixaban_D-009.pdf",
     "indication_de": "Zur Prophylaxe venöser Thromboembolien (VTE) bei erwachsenen Patienten nach elektiven Hüft- oder Kniegelenksersatzoperationen.",
     "groups": [
      {
       "group_de": "a) Patienten mit elektiver Kniegelenksersatzoperation",
       "comparator_de": "Niedermolekulare Heparine (Enoxaparin)",
       "verdict_de": "Kein Beleg für einen Zusatznutzen von Apixaban.",
       "cost": {
        "label_de": "Therapiekosten pro Patient / Operation",
        "text": "65,97 € - 103,19 €",
        "min": 65.97,
        "max": 103.19,
        "comparator_de": "Enoxaparin 108,48 €",
        "currency": "EUR",
        "kind": "HTA figure",
        "source_id": "de-gba",
        "url": "https://www.g-ba.de/downloads/91-1385-5/2012-09-06_Geltende-Fassung_Apixaban_D-009.pdf",
        "date_read": "2026-10-09",
        "line": "G-BA 2011-06-15-D-009, Beschluss vom 7. Juni 2012 / 6. September 2012, BAnz AT 03.07.2012 B2 / BAnz AT 20.09.2012 B3"
       }
      },
      {
       "group_de": "b) Patienten mit elektiver Hüftgelenksersatzoperation",
       "comparator_de": "Niedermolekulare Heparine (Enoxaparin)",
       "verdict_de": "Hinweis für einen geringen Zusatznutzen von Apixaban",
       "cost": {
        "label_de": "Therapiekosten pro Patient / Operation",
        "text": "216,27 € - 245,02 €",
        "min": 216.27,
        "max": 245.02,
        "comparator_de": "Enoxaparin 108,48 € - 216,96 €",
        "currency": "EUR",
        "kind": "HTA figure",
        "source_id": "de-gba",
        "url": "https://www.g-ba.de/downloads/91-1385-5/2012-09-06_Geltende-Fassung_Apixaban_D-009.pdf",
        "date_read": "2026-10-09",
        "line": "G-BA 2011-06-15-D-009, Beschluss vom 7. Juni 2012 / 6. September 2012, BAnz AT 03.07.2012 B2 / BAnz AT 20.09.2012 B3"
       }
      }
     ]
    }
   ],
   "ipt": []
  },
  "levetiracetam": {
   "nice": [],
   "smc": [
    {
     "id": "661/10",
     "medicine": "levetiracetam (Keppra)",
     "date": "2011-01-17",
     "submission": "Abbreviated",
     "status": "Restricted",
     "indication": "Adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in children and infants from 1 month of age to 4 years with epilepsy",
     "url": "https://scottishmedicines.org.uk/medicines-advice/levetiracetam-keppra-abbreviatedsubmission-66110/"
    },
    {
     "id": "394/07",
     "medicine": "levetiracetam 250, 500, 750 and 1000mg tablets and levetiracetam oral solution 100mg/ml (Keppra)",
     "date": "2007-09-10",
     "submission": "Full",
     "status": null,
     "indication": "Adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in children from 4 years of age with epilepsy",
     "url": "https://scottishmedicines.org.uk/medicines-advice/levetiracetam-250-500-750-and-1000mg-tablets-and-levetiracetam-oral-solution-100mgml-keppra-fullsubmission-39407/"
    },
    {
     "id": "395/07",
     "medicine": "levetiracetam 250, 500, 750 and 1000mg tablets and levetiracetam oral solution 100mg/ml (Keppra)",
     "date": "2007-09-10",
     "submission": "Full",
     "status": null,
     "indication": "as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy",
     "url": "https://scottishmedicines.org.uk/medicines-advice/levetiracetam-250-500-750-and-1000mg-tablets-and-levetiracetam-oral-solution-100mgml-keppra-fullsubmission-39507/"
    },
    {
     "id": "396/07",
     "medicine": "levetiracetam 250, 500, 750 and 1000mg tablets and levetiracetam oral solution 100mg/ml (Keppra)",
     "date": "2007-09-10",
     "submission": "Full",
     "status": null,
     "indication": "as adjunctive therapy in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with generalised idiopathic epilepsy.",
     "url": "https://scottishmedicines.org.uk/medicines-advice/levetiracetam-250-500-750-and-1000mg-tablets-and-levetiracetam-oral-solution-100mgml-keppra-fullsubmission-39607/"
    },
    {
     "id": "397/07",
     "medicine": "levetiracetam 250, 500, 750 and 1000mg tablets and levetiracetam oral solution 100mg/ml (Keppra)",
     "date": "2007-09-10",
     "submission": "Full",
     "status": null,
     "indication": "as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy",
     "url": "https://scottishmedicines.org.uk/medicines-advice/levetiracetam-250-500-750-and-1000mg-tablets-and-levetiracetam-oral-solution-100mgml-keppra-fullsubmission-39707/"
    },
    {
     "id": "311/06",
     "medicine": "levetiracetam 500mg/5ml concentrate for infusion (Keppra)",
     "date": "2006-10-09",
     "submission": "Abbreviated",
     "status": null,
     "indication": "Epilepsy",
     "url": "https://scottishmedicines.org.uk/medicines-advice/levetiracetam-500mg5ml-concentrate-for-infusion-keppra-abbreviatedsubmission-31106/"
    },
    {
     "id": "151/04",
     "medicine": "levetiracetam (Keppra®) 100mg oral solution",
     "date": "2005-01-10",
     "submission": "Abbreviated",
     "status": "Restricted",
     "indication": "Epilepsy",
     "url": "https://scottishmedicines.org.uk/medicines-advice/levetiracetam-keppra-100mg-oral-solution-abbreviatedsubmission-15104/"
    },
    {
     "id": "150/04",
     "medicine": "levetiracetam (Keppra®) 750 mg tablets",
     "date": "2005-01-10",
     "submission": "Abbreviated",
     "status": "Restricted",
     "indication": "Epilepsy",
     "url": "https://scottishmedicines.org.uk/medicines-advice/levetiracetam-keppra-750-mg-tablets-abbreviatedsubmission-15004/"
    }
   ],
   "gba": [],
   "ipt": []
  },
  "insulin-glargine": {
   "nice": [],
   "smc": [
    {
     "id": "SMC2235",
     "medicine": "insulin glargine/lixisenatide (Suliqua)",
     "date": "2020-04-13",
     "submission": "Full",
     "status": null,
     "indication": "In combination with metformin for the treatment of adults with type II diabetes mellitus (T2DM), to improve glycaemic control when this has not been provided by metformin alone or metformin combined with another oral glucose-lowering medicinal product or with basal insulin.",
     "url": "https://scottishmedicines.org.uk/medicines-advice/insulin-glarginelixisenatide-suliqua-full-smc2235/"
    },
    {
     "id": "1078/15",
     "medicine": "insulin glargine (Toujeo)",
     "date": "2015-09-07",
     "submission": "Abbreviated",
     "status": "Restricted",
     "indication": "For the treatment of type 1 or type 2 diabetes mellitus in adults aged 18 years and above",
     "url": "https://scottishmedicines.org.uk/medicines-advice/insulin-glargine-toujeo-abbreviatedsubmission-107815/"
    },
    {
     "id": "860/13",
     "medicine": "insulin glargine (Lantus)",
     "date": "2013-04-08",
     "submission": "Abbreviated",
     "status": "Restricted",
     "indication": "For the treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above.",
     "url": "https://scottishmedicines.org.uk/medicines-advice/insulin-glargine-lantus-abbreviatedsubmission-86013/"
    },
    {
     "id": "456/08",
     "medicine": "insulin glargine (Lantus Solostar)",
     "date": "2008-04-07",
     "submission": "Abbreviated",
     "status": "Restricted",
     "indication": "For the treatment of adults, adolescents and children of 6 years and above with diabetes mellitus, where treatment with insulin is required.",
     "url": "https://scottishmedicines.org.uk/medicines-advice/insulin-glargine-lantus-solostar-abbreviatedsubmission-45608/"
    },
    {
     "id": "11/02",
     "medicine": "Insulin glargine (Lantus®)",
     "date": "2002-10-04",
     "submission": "Full",
     "status": "Restricted",
     "indication": "Diabetes mellitus",
     "url": "https://scottishmedicines.org.uk/medicines-advice/insulin-glargine-lantus-fullsubmission-1102/"
    }
   ],
   "gba": [],
   "ipt": []
  }
 }
}